



Neuland Q1FY21 income at Rs.206.1 crore; up 13.5% EBITDA margins improve by 619 bps

Hyderabad, India, August 4, 2020 - Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the first quarter (Q1FY21) ended June 30, 2020.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said *“We have turned in another strong quarter with highest ever quarterly revenues of Rs. 206.1 cr. The revenue growth of 13.5% was led by all round growth in both GDS and CMS verticals. This is a creditable performance in challenging times and credit is due to our employees who rose to the occasion and ensured this quarter passed off without any major impact to the business. We believe this sets the pedestal for our performance for the rest of the fiscal.”*

In addition, Mr. Saharsh Davuluri, Joint Managing Director, Neuland Labs added *“CMS continues to drive our overall revenue momentum; the growth is attributable to both commercial as well as development products. GDS, specifically, the speciality segment is displaying good traction and we see this business complementing our CMS vertical going forward.”*

Financial Summary

Rs. crore

Particulars	Q1FY21	Q4FY20	QoQ (Growth%)	Q1FY20	YoY (Growth%)
Total Income	206.1	193.6	6.4%	181.5	13.5%
EBITDA	34.4	31.8	8.4%	19.1	80.4%
EBITDA margin (%)	16.7%	16.4%	30 bps	10.5%	619 bps
PAT	15.1	-9.3*		5.6	168.2%
PAT margin (%)	7.3%	-4.8%		3.1%	421 bps
EPS (Basic) Rs.	11.74	-7.29		4.38	168.2%

*This was after a one-time tax charge of Rs.23.2 cr in Q4FY20 that the company chose to exercise under Section 115BAA of the IT Act



Q1 FY21 Earnings Call

The company will conduct a one-hour Earnings call at **17:00 hrs. IST on Tuesday, August 4th, 2020** where the management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1107 / +91 22 7115 8008**. Other numbers are listed in the conference call invite which is posted on our website. Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 35 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 880+ Regulatory filings in the US (55 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600, Email: ir@neulandlabs.com

Diwakar Pingle, Christensen

Email: dpingle@christensenir.com

Jenna Palmieri, Neuland Laboratories Inc., USA

Email: jenna@neulandlabs.com